Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Google Secures Pentagon AI Deal for Classified Projects 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Orion Group purchased a controlling stake in LegoChem Biosciences, a South Korean research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines. The confectionery company is acquiring a 25.7% stake worth KRW550 billion or around $418 million.
With the size of its acquisition, the Orion Group has now become the largest shareholder of LegoChem Biosciences. The firm made the deal as it seeks to broaden its business and enter into new drug development business beyond antibody-drug conjugate platform technology, as per the Korea Joongang Daily.
What is Included in the Agreement
Pan Orion Corporation, the Hong Kong-headquartered subsidiary of the Orion Group, led the acquisition deal. Based on the reports, the agreement includes a combination of share purchases and rights offerings.
Moreover, it was stated in the electronic disclosure of the Financial Supervisory Service that Orion will buy 7.96 million units of new stakes at KRW59,000 per share. In addition, it will also purchase 1.4 million existing shares at the base rate of 56,186 per share. Orion is scheduled to settle the payment for the acquisition on March 29.
Orion's Venture Into Biotech Business
The Korea Economic Daily reported that this buyout deal not only marks the Orion Group's deeper venture into the biotech industry but is also expected to help the company in achieving its goal of giving a boost to LegoChem Biosciences by providing the needed financial push for clinical development and encouraging new technology research.
Once the deal is completed, Orion will be the largest shareholder in LegoChem Biosciences. Currently, the company's chief executive officer, Kim Yong Zu, holds the biggest share, and after the acquisition, he will still retain some of his shares and keep his CEO position. LegoChem is also set to become one of the confectionery giant's affiliates.
Photo by: Orion Website
